Amara Fahmy, Hafez Sherif, Orabi Abbas, El Etriby Adel, Abdel Rahim Aly Ahmed, Zakaria Ebtissam, Koura Farouk, Talaat Farouk Mohamed, Gawish Hanan, Attia Ihab, Abdel Aziz Mohamed Fahmy, El Hefnawy Mohamed Hesham Mohamed Fahmy, Kamar Mohamed, Halawa Mohamed Reda, El-Sayed Mohamed Shawky, El Kafrawy Nabil Abdelfatah, Khalil Samir Helmy Assaad, Assaad Samir Naem
Emeritus Professor of Endocrinology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Curr Diabetes Rev. 2019;15(4):340-345. doi: 10.2174/1573399815666190226150402.
Diabetic polyneuropathy (DPN) is a complex and multifactorial entity in which various factors besides hyperglycemia play an important role. Symptoms of DPN are sensory, motor or autonomic. Intensive research proved that oxidative stress is the common denominator for the four major destructive pathways of hyperglycemia including increased hexosamine pathway flux, activation of Protein kinase-C (PKC) pathway, increased Advanced Glycated End-products (AGEs) formation, and increased Polyol Pathway flux. National data in Egypt confirms that more than 60% of Egyptian diabetic patients suffer from neuropathy. The most common complications of DPN are Cardiac Autonomic Neuropathy (CAN), diabetic foot and ulcers, neuromuscular disability, and anxiety. In addition, DPN affects the Quality of Life (QoL). According to common clinical practice, the common diagnostic tools are bed-side diagnosis and electrophysiological tests. Early diagnosis is critical to improve the prognosis of DPN and therapeutic intervention in the early phase. In this review, we provide a clear understanding of the pathogenesis, early diagnosis and the good management of DPN. Since the pathogenesis of DPN is multifactorial, its management is based on combination therapy of symptomatic; either pharmacological or non-pharmacological treatments, and pathogenic treatment. Alpha Lipoic Acid (ALA) is a potent anti-oxidant that has several advantages as a pathogenic treatment of DPN. So, in clinical practice, ALA may be prescribed for patients with early neuropathic deficits and symptoms. Patient education has an important role in the managemement of DPN.
糖尿病性多发性神经病变(DPN)是一种复杂的多因素病症,其中除高血糖外的多种因素也起着重要作用。DPN的症状包括感觉、运动或自主神经症状。深入研究证明,氧化应激是高血糖四大主要破坏途径的共同特征,这些途径包括己糖胺途径通量增加、蛋白激酶C(PKC)途径激活、晚期糖基化终产物(AGEs)形成增加以及多元醇途径通量增加。埃及的全国数据证实,超过60%的埃及糖尿病患者患有神经病变。DPN最常见的并发症是心脏自主神经病变(CAN)、糖尿病足和溃疡、神经肌肉残疾以及焦虑。此外,DPN会影响生活质量(QoL)。根据常见临床实践,常用的诊断工具是床边诊断和电生理检查。早期诊断对于改善DPN的预后以及早期进行治疗干预至关重要。在本综述中,我们对DPN的发病机制、早期诊断和良好管理进行了清晰的阐述。由于DPN的发病机制是多因素的,其管理基于对症治疗的联合疗法,包括药物或非药物治疗以及病因治疗。α硫辛酸(ALA)是一种有效的抗氧化剂,作为DPN的病因治疗具有多个优点。因此,在临床实践中,对于有早期神经病变缺陷和症状的患者可以开具ALA处方。患者教育在DPN的管理中具有重要作用。